HIV-1-INFECTION

This study investigates whether combining two immune checkpoint inhibitors—one targeting GARP:TGF-β1 and another targeting PD-1—can better reactivate and eliminate dormant HIV-infected cells. Using blood samples from people with HIV-1 on suppressive antiretroviral therapy, resear…

This study tests an experimental RNA-based vaccine called BNT168 in adults both with and without HIV. The goal is to see if the vaccine is safe, triggers an immune response, and can help control the amount of virus in the body. Participants receive either the vaccine or a placebo…

This trial is testing whether a 10-week course of fluconazole works as well as the standard 24-week course for people with HIV who have a cryptococcal infection in their blood (antigenemia) but no symptoms. It also compares starting HIV medications right away versus waiting 14 da…

This study tests a program to help people with HIV who also have high blood pressure stick to their medication. Participants will get educational materials, a home blood pressure monitor, and regular check-ins with a nurse. The goal is to see if this approach is practical and hel…

This early-stage trial is testing an experimental drug called GS-0415 in people with HIV who already have the virus well-controlled by standard antiretroviral therapy. The study will give single and multiple doses of GS-0415 to evaluate its safety, tolerability, and how the body …

This study tests whether adding Qiling Yiqi tablets, a Chinese herbal medicine, to standard HIV therapy can improve immune function in people whose CD4 counts remain low despite successful viral suppression. The trial involves 240 adults with HIV who have been on antiretroviral t…

This study tests whether adding Fuyang Jiedu Granules, a traditional Chinese herbal mixture, to standard antiretroviral therapy can improve immune function in people with HIV who have persistently low CD4 counts despite viral suppression. The trial includes 240 adults aged 18–60 …

This trial tests whether adding a lab-made antibody (ePGT121v1-LS) to standard HIV medication can help infants under one year old achieve better viral suppression. About 87 infants in South Africa will receive either the antibody or a placebo injection every 12 weeks for 48 weeks…

This trial tests whether adding two lab-made antibodies (ePGT121v1-LS and VRC07-523-LS) to standard antiretroviral therapy can help infants living with HIV achieve viral suppression. Infants up to one year old in Mozambique and Cameroon receive four injections of the antibodies o…

This early-stage study tests whether two lab-made antibodies can help people with HIV control the virus after stopping their regular antiretroviral therapy. The 40 participants all started HIV treatment very early after infection. Researchers will monitor safety and see if the an…

This study looks at how long-acting injectable HIV drugs (cabotegravir and rilpivirine) work in the body during pregnancy and after childbirth. About 40 pregnant women with HIV will receive the shots every 4 weeks. The goal is to measure drug levels and see if they stay effective…

This study will test a two-drug HIV pill (Dolutegravir/Lamivudine) in 210 pregnant women who have never taken HIV medication. The goal is to see if it controls the virus and prevents passing HIV to their babies. Participants will be compared to those on standard three-drug therap…

This study tests a program called iSYV that combines peer-led group sessions with a gamified text-message game to support mental health and HIV care for 5,000 youth aged 15-24 in Tanzania. The goal is to see if it helps them keep their virus under control and stay in care. The pr…

This study looks at whether people with HIV who are already well-controlled on daily pills can switch to a long-acting injection given every two months. The goal is to see how many stay on the injection without stopping or needing to change treatment over 48 weeks. The study will…

This study looks at how well a long-acting combination of two HIV drugs (cabotegravir and lenacapavir) works in 50 adults with HIV-1. Participants either already take this treatment or will start it by doctor's order. The main goal is to see if the virus stays suppressed (below 5…

This early-stage trial tests whether a combination of three existing drugs (topiramate, lenalidomide, and pyrimethamine) can wake up dormant HIV hiding in the body and then help the immune system eliminate those infected cells. The goal is a 'functional cure' where the virus is c…

This study tests whether two different chemotherapy drugs, paclitaxel and pegylated liposomal doxorubicin, work equally well for treating Kaposi sarcoma in people living with HIV in sub-Saharan Africa. About 130 participants will receive one of the drugs every three weeks for six…

This study tests whether a once-daily pill containing doravirine, lamivudine, and tenofovir can quickly control HIV in people who have never taken HIV drugs before. One hundred newly diagnosed adults will take the pill for 48 weeks. The main goal is to see how many have undetecta…

This study looks at how HIV-1 hides in immune cells in the gut of people on effective antiretroviral therapy. Researchers will collect blood and colon tissue from 30 HIV-positive volunteers and healthy controls during routine colonoscopies. The goal is to understand why these gut…

This study will give a single dose of oral methamphetamine to 20 people with HIV who are on effective antiretroviral therapy and have undetectable virus levels. The goal is to see if the drug can temporarily wake up dormant HIV hiding in cells, which could help researchers find n…